Showing 4261-4270 of 7411 results for "".
- Viscot Medical Introduces the AllSkin Plus+https://practicaldermatology.com/news/20130110-viscot_medical_introduces_the_allskin_plus/2459644/Viscot Medical released the AllSkin Plus+, a prep resistant ink marker that offers maximum visibility and prep resistance on all skin tones. According to the company, the VIXL brilliant blue ink provides enhanced visibility even after prepping with
- Apremilast Meets Endpoints in Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/20130108-apremilast_meets_endpoints_in_phase_3_psoriasis_trials/2459645/Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving apremilast 30 mg BID monotherapy in both the ESTEEM
- Layoffs at Medicis top 300, with 117 staffers chosen to stayhttps://practicaldermatology.com/news/20130104-layoffs_at_medicis_top_300_with_117_staffers_chosen_to_stay/2459648/The layoff toll at Medicis Pharmaceutical has topped 300, the Phoenix Business Journal reports. Valeant Pharmaceuticals ($VRX), which wrapped up its buyout of the Arizona-based skin drug company last week, has cut 319 staffers--and kept 117--as it integrates Medicis into its own dermatology operatio
- Valeant Pharmaceuticals Appoints New Managementhttps://practicaldermatology.com/news/20130103-valeant_pharmaceuticals_appoints_new_management/2459649/Valeant Pharmaceuticals International, Inc. named Laizer D. Kornwasser the Executive Vice President/Company Group Chairman, where he will be responsible for operations in Canada, US Neurology, and managed care and distribution, effective February
- North American Facial Injectable Market to Hit $1.7 Billion by 2017https://practicaldermatology.com/news/20121228-north_american_facial_injectable_market_to_hit_17_billion_by_2017/2459652/According to Millennium Research Group, the North American facial injectables market, comprising botulinum toxin and dermal fillers sold in the US and Canada, will continue to show strong growth for the next five years, reaching a total value of more
- Goldfaden MD to Donate to American Heart Association in 2013https://practicaldermatology.com/news/20121218-goldfaden_md_to_donate_to_american_heart_association_in_2013/2459656/Goldfaden MD plans to launch its Hands To Heart Anti-Aging Plus Brightening Hand Treatment in February 2013. In addition, ten percent of all proceeds from these purchases in February will be donated to the American Heart Association. The fast-
- Murad Names Suzanne Dawson Chief Marketing Officerhttps://practicaldermatology.com/news/20121213-murad_names_suzanne_dawson_chief_marketing_officer/2459658/Murad Inc. named Suzanne Dawson Chief Marketing Officer, overseeing all global marketing including brand development, advertising, public relations, creative, and education, for products, services, and new market opportunities. Dawson comes to Murad
- ARTAS System Adopted by Minneapolis Surgeonhttps://practicaldermatology.com/news/20121204-artas_system_adopted_by_minneapolis_surgeon/2459664/Restoration Robotics, Inc. announced the first use of its revolutionary ARTAS System in Minneapolis by Dr. Ron Shapiro of Shapiro Medical Group. The ARTAS System is the first and only FDA-cleared, physician-controlled, computer-assisted technolo
- Merz, Inc. Acquires ONMEL Oral Treatment for Toenail Fungal Infectionshttps://practicaldermatology.com/news/20121128-merz_inc_acquires_onmel_oral_treatment_for_toenail_fungal_infections/2459671/Merz, Inc. completed the acquisition of ONMEL (itraconazole), an azole antifungal indicated for the oral treatment of onychomycosis of the toenail caused by Trichophyton rubrumor T. Mentagrophytes in non-immunocompromised patients. According to the compa
- Valeant Receives FTC Clearance For Medicis Acquisitionhttps://practicaldermatology.com/news/20121121-valeant_receives_ftc_clearance_for_medicis_acquisition/2459676/The US Federal Trade Commission (FTC) granted early termination of the waiting period surrounding the proposed acquisition of Medicis Pharmaceutical Corporation by Valeant Pharmaceuticals International, Inc., effective November 15, 2012. The propo